SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-208713
Filing Date
2020-08-04
Accepted
2020-08-04 06:52:37
Documents
14
Period of Report
2020-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d272620d8k.htm   iXBRL 8-K 25233
2 EX-99.1 d272620dex991.htm EX-99.1 117172
6 GRAPHIC g272620g0803225828005.jpg GRAPHIC 2825
  Complete submission text file 0001193125-20-208713.txt   278561

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epzm-20200804.xsd EX-101.SCH 3065
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epzm-20200804_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epzm-20200804_pre.xml EX-101.PRE 10949
7 EXTRACTED XBRL INSTANCE DOCUMENT d272620d8k_htm.xml XML 3218
Mailing Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 4TH FLOOR CAMBRIDGE MA 02139 617-229-5872
Epizyme, Inc. (Filer) CIK: 0001571498 (see all company filings)

IRS No.: 261349956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35945 | Film No.: 201070893
SIC: 2834 Pharmaceutical Preparations